Sanofi And Hengrui To Go To Court Again
This article was originally published in PharmAsia News
Executive Summary
In response to the verdict of non-patent infringement of Hengrui's use of docetaxel in China, Sanofi-Aventis is likely to appeal to the Beijing Number One Intermediate People's Court to further fight for its patent rights. The Greater China office says that it cannot comment on the case now but states that Sanofi holds the patent for docetaxel worldwide and its team of lawyers is preparing the necessary legal documents. Industry observers believe Sanofi is not likely to give up its fight for the patent as Taxotere, its key antitumor product using docetaxel, fetches a lucrative profit. (Click here for more - Chinese Language)
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.